Sales are now seen at roughly 48-49 billion euros ($53-$54 billion), up from a previous goal of about 46 billion euro, with currency effects giving a boost of about 9 percent, up from 3 percent it had previously expected .
Bayer is now banking on 2015 adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) to grow by "a high-teens percentage", where it had previously seen a "low- to mid-teens percentage" increase.
Also read: Factors to watch on Jan 17
16:22 Trump's first 100 days: Here's what to expect from the market21
16:50 Goldman Sachs, Citigroup earnings confirm Trump effect on banks19
12:23 Morgan Stanley beats, has a record-breaking quarter for wealth management18
12:23 Sterling volatile as market speculates on ‘hard Brexit’; investors await May's speech18